Skip to main content

 Scientific publications

HER2-targeted treatment for older patients with breast cancer: An expert position paper from the International Society of Geriatric Oncology.

Authors : Brain E, Caillet P, de Glas N, Biganzoli L, Cheng K, Dal Lago L, Wildiers H
Year : 2019
Journal : J Geriatr Oncol

Characterization of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.

Authors : Cardoso F, Bartlett JMS, Slaets L, van Deurzen CHM, van Leeuwen-Stok E, Porter P, Linderholm B, Hedenfalk I, Schröder C, Martens J, Bayani J, van Asperen C, Murray M, Hudis C, Middleton L, Vermeij J, Punie K, Fraser J, Nowaczyk M, Rubio IT, Aebi S, Kelly C, Ruddy KJ, Winer E, Nilsson C, Dal Lago L, Korde L, Benstead K, Bogler O, Goulioti T, Peric A, Litière S, Aalders KC, Poncet C, Tryfonidis K, Giordano SH
Year : 2018
Journal : Ann Oncol
Volume : 29(2)
Pages : 405-417

Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.

Authors : Wildiers H, Tryfonidis K, Dal Lago L, Vuylsteke P, Curigliano G, Waters S, Brouwers B, Altintas S, Touati N, Cardoso F, Brain E
Year : 2018
Journal : Lancet Oncol
Volume : 19
Pages : 323-336

The effect of adjuvant chemotherapy on symptom burden and quality of life over time; a preliminary prospective observational study using individual data of patients aged =70 with early stage invasive breast cancer.

Authors : Quinten C, Kenis C, Hamaker M, Coolbrandt A, Brouwers B, Dal Lago L, Neven P, Vuylsteke P, Debrock G, Van den Bulck H, Smeets A, Schöffski P, Bottomley A, Wedding U, Wildiers H
Year : 2018
Journal : J Geriatr Oncol
Volume : 9(2)
Pages : 152-162

Old age: An extra risk for febrile neutropenia?

Authors : Klastersky J, Dal Lago L
Year : 2017
Journal : J Geriatr Oncol
Volume : 8(2)
Pages : 84-85

Adjuvant chemotherapy in elderly patients with breast cancer: key challenges.

Authors : Pondé N, Dal Lago L, Azim HA Jr
Year : 2016
Journal : Expert Rev Anticancer Ther
Volume : 16(6)
Pages : 661-71

The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters.

Authors : Brouwers B, Hatse S, Dal Lago L, Neven P, Vuylsteke P, Dalmasso B, Debrock G, Van den Bulck H, Smeets A, Bechter O, Kini Bailur J, Kenis C, Laenen A, Schöffski P, Pawelec G, Journe F, Ghanem G, Wildiers H
Year : 2016
Journal : Oncotarget
Volume : 7(21)
Pages : 29977-88

What is the role of informed decision-making?

Authors : Pondé N, Dal Lago L, Azim HA Jr
Year : 2016
Journal : Expert Rev Anticancer Ther
Volume : 16(9)
Pages : 893

Drugs prescribed for patients hospitalized in a geriatric oncology unit: Potentially inappropriate medications and impact of a clinical pharmacist.

Authors : Deliens C, Deliens G, Filleul O, Pepersack T, Awada A, Piccart-Gebhart M, Praet JP, Dal Lago L
Year : 2016
Journal : J Geriatr Oncol
Volume : 7(6)
Pages : 463-70

Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer.

Authors : Ignatiadis M, Zardavas D, Lemort M, Wilke C, Vanderbeeken MC, Dhondt V, de Azambuja E, Gombos A, Lebrun F, Dal Lago L, Bustin F, Maetens M, Ameye L, Veys I, Michiels S, Paesmans M, Larsimont D, Sotiriou C, Nogaret JM, Piccart-Gebhart M, Awada A
Year : 2016
Journal : PLoS ONE
Volume : 11(7)
Pages : e0154009

Clinical research in febrile neutropenia in cancer patients:Past achievements and perspectives for the future

Authors : Klastersky J, Paesmans M, Aoun M, Georgala A, Loizidou A, Lalami Y, Dal Lago L
Year : 2016
Journal : World J Clin Infect Dis
Volume : 6(3)
Pages : 37-60

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.

Authors : Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, + collaborators (among others :, Dal Lago L, de Azambuja E, Dabakuyo-Yonli TS
Year : 2015
Journal : Ann Oncol
Volume : 26(5)
Pages : 873-879.

Information perception, wishes, and satisfaction in ambulatory cancer patients under active treatment: patient-reported outcomes with QLQ-INFO25.

Authors : Pinto AC, Ferreira-Santos F, Dal Lago L, de Azambuja E, Pimentel FL, Piccart-Gebhart M, Razavi D
Year : 2014
Journal : Ecancermedicalscience
Volume : 8(null)
Pages : 425

Evaluating the physiological reserves of older patients with cancer: the value of potential biomarkers of aging?

Authors : Pallis AG, Hatse S, Brouwers B, Pawelec G, Falandry C, Wedding U, Dal Lago L, Repetto L, Ring A, Wildiers H
Year : 2014
Journal : J Geriatr Oncol
Volume : 5(2)
Pages : 204-18

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.

Authors : Goldhirsch A, Gelber Rd, Piccart-Gebhart M, de Azambuja E, Procter M, Suter TM, Jackisch C, Cameron D, Weber HA, Heinzmann D, Dal Lago L, Mcfadden E, Dowsett M, Untch M, Gianni L, Bell R, Köhne CH, Vindevoghel A, Andersson M, Brunt AM, Otero-Reyes D, Song S, Smith I, Leyland-Jones B, Baselga J
Year : 2013
Journal : Lancet
Volume : 382(9897)
Pages : 1021-8

Clinical development of insulin-like growth factor receptor-1 (IGF-1R) inhibitors: At the crossroad?

Authors : Gombos A, Metzger-Filho O, Dal Lago L, Awada A
Year : 2012
Journal : Invest New Drugs
Volume : 30(6)
Pages : 2433-42

Envelhecimento e doença crônica - editorial

Authors : Dal Lago L
Year : 2011
Journal : Revista da AMRIGS, Porto Allegre
Volume : 55(1)
Pages : 5-6p

The Research Ethics Committee at Universidade Federal de Santa Maria: a brief historical review

Authors : Nardin Weis L, Hundertmarck Minato E, Borges Fagundes R, Bins di Napoli R, Emando Silva C, de Campos Velho MTA, Dal Lago L
Year : 2011
Journal : Revista HCPA
Volume : 31(3)
Pages : 372-76